Literature DB >> 15561776

SRC regulates actin dynamics and invasion of malignant glial cells in three dimensions.

Alexandre Angers-Loustau1, Ramm Hering, Tamra E Werbowetski, David R Kaplan, Rolando F Del Maestro.   

Abstract

Malignant glioma is the major brain tumor in adults and has a poor prognosis. The failure to control invasive cell subpopulations may be the key reason for local glioma recurrence after radical tumor resection and may contribute substantially to the failure of the other treatment modalities such as radiation therapy and chemotherapy. As a model for this invasion, we have implanted spheroids from a human glioma cell line (U251) in three-dimensional collagen type I matrices, which these cells readily invade. We first observed that the Src family kinase-specific pharmacologic inhibitors PP2 and SU6656 significantly inhibited the invasion of the cells in this assay. We confirmed this result by showing that expression of two inhibitors of Src family function, dominant-negative-Src and CSK, also suppressed glioma cell invasion. To characterize this effect at the level of the cytoskeleton, we used fluorescent time-lapse microscopy on U251 cells stably expressing a YFP-actin construct and observed a rapid change in actin dynamics following addition of PP2 in both two-dimensional and three-dimensional cultures. In monolayer cultures, PP2 caused the disappearance of peripheral membrane ruffles within minutes. In three-dimensional cultures, PP2 induced the loss of actin bursting at the leading tip of the invadopodium. The inhibition of Src family activity is thus a potential therapeutic approach to treat highly invasive malignant glioma.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15561776

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  34 in total

Review 1.  Thyroid hormone receptors and cancer.

Authors:  Won Gu Kim; Sheue-yann Cheng
Journal:  Biochim Biophys Acta       Date:  2012-04-06

2.  Assessing the cytoskeletal system and its elements in C6 glioma cells and astrocytes by atomic force microscopy.

Authors:  Dexiang Zhou; Xiaodan Jiang; Ruxiang Xu; Yingqian Cai; Jiliang Hu; Gang Xu; Yuxi Zou; Yanjun Zeng
Journal:  Cell Mol Neurobiol       Date:  2008-03-04       Impact factor: 5.046

3.  KX2-361: a novel orally bioavailable small molecule dual Src/tubulin inhibitor that provides long term survival in a murine model of glioblastoma.

Authors:  Michael J Ciesielski; Yahao Bu; Stephan A Munich; Paola Teegarden; Michael P Smolinski; James L Clements; Johnson Y N Lau; David G Hangauer; Robert A Fenstermaker
Journal:  J Neurooncol       Date:  2018-09-20       Impact factor: 4.130

4.  Src family kinases differentially influence glioma growth and motility.

Authors:  Laura J Lewis-Tuffin; Ryan Feathers; Priya Hari; Nisha Durand; Zhimin Li; Fausto J Rodriguez; Katie Bakken; Brett Carlson; Mark Schroeder; Jann N Sarkaria; Panos Z Anastasiadis
Journal:  Mol Oncol       Date:  2015-06-10       Impact factor: 6.603

5.  Extracellular cholesterol-rich microdomains generated by human macrophages and their potential function in reverse cholesterol transport.

Authors:  Daniel S Ong; Joshua J Anzinger; Francisco J Leyva; Noa Rubin; Lia Addadi; Howard S Kruth
Journal:  J Lipid Res       Date:  2010-04-26       Impact factor: 5.922

6.  Fusicoccin a, a phytotoxic carbotricyclic diterpene glucoside of fungal origin, reduces proliferation and invasion of glioblastoma cells by targeting multiple tyrosine kinases.

Authors:  Marina Bury; Anna Andolfi; Bernard Rogister; Alessio Cimmino; Véronique Mégalizzi; Véronique Mathieu; Olivier Feron; Antonio Evidente; Robert Kiss
Journal:  Transl Oncol       Date:  2013-04-01       Impact factor: 4.243

7.  EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.

Authors:  Enrico Franceschi; Roger Stupp; Martin J van den Bent; Carla van Herpen; Florence Laigle Donadey; Thierry Gorlia; Monika Hegi; Benoit Lhermitte; Lewis C Strauss; Anouk Allgeier; Denis Lacombe; Alba A Brandes
Journal:  Neuro Oncol       Date:  2012-10-22       Impact factor: 12.300

8.  Mesenchymal migration as a therapeutic target in glioblastoma.

Authors:  Jessie Zhong; Andre Paul; Stewart J Kellie; Geraldine M O'Neill
Journal:  J Oncol       Date:  2010-06-21       Impact factor: 4.375

9.  EGF regulates plasminogen activator inhibitor-1 (PAI-1) by a pathway involving c-Src, PKCdelta, and sphingosine kinase 1 in glioblastoma cells.

Authors:  Barbara S Paugh; Steven W Paugh; Lauren Bryan; Dmitri Kapitonov; Katarzyna M Wilczynska; Sunita M Gopalan; Hanna Rokita; Sheldon Milstien; Sarah Spiegel; Tomasz Kordula
Journal:  FASEB J       Date:  2007-09-12       Impact factor: 5.191

Review 10.  Receptor "hijacking" by malignant glioma cells: a tactic for tumor progression.

Authors:  Jian Huang; Keqiang Chen; Wanghua Gong; Ye Zhou; Yingying Le; Xiuwu Bian; Ji Ming Wang
Journal:  Cancer Lett       Date:  2008-04-22       Impact factor: 8.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.